New study checks how much MS drug gets into breast milk

NCT ID NCT06143514

Recruiting now Knowledge-focused Sponsor: TG Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This study looks at how much of the multiple sclerosis drug BRIUMVI gets into breast milk. About 16 breastfeeding women with relapsing MS will provide milk samples after their regular treatment. The goal is to understand drug exposure for nursing infants, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis secondary progressive multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSING MULTIPLE SCLEROSIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

PROVIDE Virtual Research Coordination Center
RECRUITING

San Francisco, California, 94158, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
PROVIDE Virtual Research Coordination Center
RECRUITING

Smyrna, Georgia, 30080, United States
PROVIDE Virtual Research Coordination Center
RECRUITING

Wilmington, North Carolina, 28401-3331, United States
PROVIDE Virtual Research Coordination Center
RECRUITING

Nashville, Tennessee, 37215, United States
TG Therapeutics Investigational Trial Site
RECRUITING

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.